Abstract: A method for forming an optimized radiation shield design for a component including providing a computer system programmed to generate data files that define a component radiation shield having an optimized design based on pre-stored data defining particular radiation characteristics and user-provided data defining radiation shield design criteria. Radiation shield design criteria are inputted into the computer system which processes the inputted radiation shield design criteria and the pre-stored data defining particular radiation characteristics in order to generate data files defining an optimized design for a component radiation shield. The generated data files defining the optimized design for a component radiation shield are provided to a metallic three-dimensional printing system. The three-dimensional printing system is then activated to form a component radiation shield using a predetermined metal powder and the generated data files that define the optimized component radiation shield design.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: A method and system is provided for a merchant to display live streaming video feeds of live items, such as marine life, for sale to a buyer through an online e-commerce website. More specifically, the method can include placing the item within a storage vessel, positioning a video recording camera adjacent to the storage vessel, and capturing streaming video from the camera of the item. The method can further include transmitting the streaming video of the item to a client portal, receiving an order request from the client, processing the order request, updating an inventory based on the processed order request, and ceasing transmission of the streaming video to the portal based on the processed order. The method and system provide a simple, automated, and reliable method for a buyer to purchase live items from a merchant wherein the buyer can see exactly the item he or she is purchasing, including the physical condition, configuration, size, health, and overall well-being of the item.

Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: The present invention is directed to compounds of formula (I): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: A firearm holster for securely housing a firearm that is also configured so that a firearm housed in the holster can be rotated out of the holster with minimal effort. The firearm holster is also preferably easily attachable in a concealed manner to ballistics clothing.

Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

Abstract: The present invention is directed to compounds of formula(I): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.